• Oct 5, 2026

  $156.53-0.24%

• Oct 2, 2026

  $156.90-0.51%

• Oct 1, 2026

  $157.70-2.33%

  The shares fell 2.33% while the broad market, measured by the S&P 500 ETF (SPY), rose 0.18% on the same session [1]. The move was therefore not shared by the broad market [1].

  • 1Broad market

• Sep 30, 2026

  $161.47-1.67%

• Sep 29, 2026

  $164.21-1.17%

  Seeking Alpha reported that AstraZeneca filed an FDA new drug application for savolitinib with Tagrisso in second-line MET-overexpressing non-small cell lung cancer [1]. Seeking Alpha also covered a $2B strategic investment by AstraZeneca in Summit Therapeutics [2]. The shares nonetheless closed down 1.17% on the day.

  • 1Seeking Alpha
  • 2Seeking Alpha

• Sep 28, 2026

  $166.15-0.26%

  AstraZeneca shares slipped 0.26% in a quiet session. Seeking Alpha reported that AstraZeneca and Summit Therapeutics agreed a $2B convertible investment plus a GI cancer trial collaboration for ivonescimab [1]. Volume was 0.6x its trailing 20-session average, and the price stayed within a range of 1.3% of the low [2]. The items do not link the small decline to the deal.

  • 1Seeking Alpha
  • 2Market data

• Sep 25, 2026

  $166.58+1.23%

Closing prices for AZN. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.